Punctal plug performs well at Phase II

Article

The Latanoprost punctal plug drug delivery system (L-PPDS) has performed well in its Phase II CORE trial, according to study data released by the manufacturer, QLT Plug Delivery Inc.

The Latanoprost punctal plug drug delivery system (L-PPDS) has performed well in its Phase II CORE trial, according to study data released by the system's manufacturer, QLT Plug Delivery Inc.

Thirty-eight patients implanted with the L-PPDS, a non-invasive sustained-release drug-eluting device, completed 12 weeks of follow-up in the randomized, double-masked, multicentre study. The patients had a mean age of 65 years (range: 40–87 years) and a mean baseline intraocular pressure (IOP) of 24.4±2.1 mmHg. Patients received a latanoprost dose of 3.5, 14 or 21 µg.

All dose groups achieved a statistically significant reduction in IOP. From baseline to week 12, the overall IOP reduction was 20%. For those receiving a high-dose of latanoprost, a mean IOP reduction of 4.9 mmHg was achieved; for a medium dose, the reduction was 4.8 mmHg, and for a low dose, the reduction was 5.4 mmHg. The L-PPDS was well tolerated; adverse events were mild and transient, and the most common instances were increased tear production and ocular discomfort.

In the next stage of the Phase II trial, QLT will investigate the use of higher doses of latanoprost (minimum 35 µg) with the L-PPDS.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.